StockData
NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Nkarta, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.75−0.05 (-2.78%)

Close on Oct 19, 2026

Market cap
$130.37M
P/E (TTM)
–
Dividend yield
0.00%

Earnings

Next report expected Nov 9, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 10, 2026During market hours–$-0.54–
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026During market hours–$-0.37–
Q4 FY2025
Ended Dec 31, 2025
Mar 25, 2026During market hours–$-0.37–
Q3 FY2025
Ended Sep 30, 2025
Nov 10, 2025During market hours–$-0.29–
Q2 FY2025
Ended Jun 30, 2025
Aug 12, 2025During market hours–$-0.31–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025During market hours–––
Q4 FY2024
Ended Dec 31, 2024
Mar 26, 2025During market hours–$-0.35–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024During market hours–$-0.39–
Q2 FY2024
Ended Jun 30, 2024
Aug 16, 2024During market hours–$-0.34–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024During market hours–$-0.58–
Q4 FY2023
Ended Dec 31, 2023
Mar 21, 2024During market hours–$-0.57–

Company guidance

Outlook given with results on Mar 26, 2025, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Cash payments resulting from the restructuringfuture$5.50M to $6.50M–

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Nkarta filed with the SEC